Pharmacologic therapy for intermittent claudication

Paul P. Dobesh, Zachary A. Stacy, Emily L. Persson

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Peripheral artery disease, defined as atherosclerosis in the lower extremities, affects nearly 8.5 million people in the United States. Due to the frequent asymptomatic manifestation of peripheral artery disease, diagnosis may be delayed and its true incidence underestimated. However, some patients may experience aching pain, numbness, weakness, or fatigue, a condition termed intermittent claudication. Peripheral atherosclerosis is associated with cardiovascular risk and physical impairment; therefore, treatment goals are aimed at decreasing cardiovascular risk, as well as improving quality of life. Little debate exists regarding the management of cardiovascular risk reduction, which consists of both antiplatelet therapy and risk factor modification. Despite recently published guidelines, the treatment of intermittent claudication is less well established and the management remains controversial and uncertain. Exercise remains the first-line therapy for intermittent claudication; however, pharmacologic treatment is often necessary. Although only two prescription drugs have been approved by the U.S. Food and Drug Administration for the treatment of intermittent claudication, several supplements and investigational agents have been evaluated. Therapeutic optimization should balance the anticipated improvements in quality of life with the potential safety risks.

Original languageEnglish (US)
Pages (from-to)526-553
Number of pages28
JournalPharmacotherapy
Volume29
Issue number5
DOIs
StatePublished - May 1 2009

Fingerprint

Intermittent Claudication
Peripheral Arterial Disease
Therapeutics
Atherosclerosis
Quality of Life
Prescription Drugs
Hypesthesia
United States Food and Drug Administration
Risk Reduction Behavior
Fatigue
Lower Extremity
Guidelines
Exercise
Safety
Pain
Incidence

Keywords

  • Angiogenesis.
  • Buflomedil
  • Cilostazol
  • Intermittent claudication
  • L-arginine
  • Naftidrofuryl
  • PAD
  • Pentoxifylline
  • Peripheral artery disease
  • Propionyl-L-carnitine
  • Statins

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Pharmacologic therapy for intermittent claudication. / Dobesh, Paul P.; Stacy, Zachary A.; Persson, Emily L.

In: Pharmacotherapy, Vol. 29, No. 5, 01.05.2009, p. 526-553.

Research output: Contribution to journalReview article

Dobesh, Paul P. ; Stacy, Zachary A. ; Persson, Emily L. / Pharmacologic therapy for intermittent claudication. In: Pharmacotherapy. 2009 ; Vol. 29, No. 5. pp. 526-553.
@article{a99967f4fd774b58b3bf721609e32761,
title = "Pharmacologic therapy for intermittent claudication",
abstract = "Peripheral artery disease, defined as atherosclerosis in the lower extremities, affects nearly 8.5 million people in the United States. Due to the frequent asymptomatic manifestation of peripheral artery disease, diagnosis may be delayed and its true incidence underestimated. However, some patients may experience aching pain, numbness, weakness, or fatigue, a condition termed intermittent claudication. Peripheral atherosclerosis is associated with cardiovascular risk and physical impairment; therefore, treatment goals are aimed at decreasing cardiovascular risk, as well as improving quality of life. Little debate exists regarding the management of cardiovascular risk reduction, which consists of both antiplatelet therapy and risk factor modification. Despite recently published guidelines, the treatment of intermittent claudication is less well established and the management remains controversial and uncertain. Exercise remains the first-line therapy for intermittent claudication; however, pharmacologic treatment is often necessary. Although only two prescription drugs have been approved by the U.S. Food and Drug Administration for the treatment of intermittent claudication, several supplements and investigational agents have been evaluated. Therapeutic optimization should balance the anticipated improvements in quality of life with the potential safety risks.",
keywords = "Angiogenesis., Buflomedil, Cilostazol, Intermittent claudication, L-arginine, Naftidrofuryl, PAD, Pentoxifylline, Peripheral artery disease, Propionyl-L-carnitine, Statins",
author = "Dobesh, {Paul P.} and Stacy, {Zachary A.} and Persson, {Emily L.}",
year = "2009",
month = "5",
day = "1",
doi = "10.1592/phco.29.5.526",
language = "English (US)",
volume = "29",
pages = "526--553",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "5",

}

TY - JOUR

T1 - Pharmacologic therapy for intermittent claudication

AU - Dobesh, Paul P.

AU - Stacy, Zachary A.

AU - Persson, Emily L.

PY - 2009/5/1

Y1 - 2009/5/1

N2 - Peripheral artery disease, defined as atherosclerosis in the lower extremities, affects nearly 8.5 million people in the United States. Due to the frequent asymptomatic manifestation of peripheral artery disease, diagnosis may be delayed and its true incidence underestimated. However, some patients may experience aching pain, numbness, weakness, or fatigue, a condition termed intermittent claudication. Peripheral atherosclerosis is associated with cardiovascular risk and physical impairment; therefore, treatment goals are aimed at decreasing cardiovascular risk, as well as improving quality of life. Little debate exists regarding the management of cardiovascular risk reduction, which consists of both antiplatelet therapy and risk factor modification. Despite recently published guidelines, the treatment of intermittent claudication is less well established and the management remains controversial and uncertain. Exercise remains the first-line therapy for intermittent claudication; however, pharmacologic treatment is often necessary. Although only two prescription drugs have been approved by the U.S. Food and Drug Administration for the treatment of intermittent claudication, several supplements and investigational agents have been evaluated. Therapeutic optimization should balance the anticipated improvements in quality of life with the potential safety risks.

AB - Peripheral artery disease, defined as atherosclerosis in the lower extremities, affects nearly 8.5 million people in the United States. Due to the frequent asymptomatic manifestation of peripheral artery disease, diagnosis may be delayed and its true incidence underestimated. However, some patients may experience aching pain, numbness, weakness, or fatigue, a condition termed intermittent claudication. Peripheral atherosclerosis is associated with cardiovascular risk and physical impairment; therefore, treatment goals are aimed at decreasing cardiovascular risk, as well as improving quality of life. Little debate exists regarding the management of cardiovascular risk reduction, which consists of both antiplatelet therapy and risk factor modification. Despite recently published guidelines, the treatment of intermittent claudication is less well established and the management remains controversial and uncertain. Exercise remains the first-line therapy for intermittent claudication; however, pharmacologic treatment is often necessary. Although only two prescription drugs have been approved by the U.S. Food and Drug Administration for the treatment of intermittent claudication, several supplements and investigational agents have been evaluated. Therapeutic optimization should balance the anticipated improvements in quality of life with the potential safety risks.

KW - Angiogenesis.

KW - Buflomedil

KW - Cilostazol

KW - Intermittent claudication

KW - L-arginine

KW - Naftidrofuryl

KW - PAD

KW - Pentoxifylline

KW - Peripheral artery disease

KW - Propionyl-L-carnitine

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=66249147909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66249147909&partnerID=8YFLogxK

U2 - 10.1592/phco.29.5.526

DO - 10.1592/phco.29.5.526

M3 - Review article

C2 - 19397462

AN - SCOPUS:66249147909

VL - 29

SP - 526

EP - 553

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 5

ER -